Search Results - Ana Arance

Molecular Markers and Targets in Melanoma by Cristina Teixido, Paola Castillo, Clara Martinez-Vila, Ana Arance, Llucia Alos

Get full text

Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients by Paola Castillo, Marta Marginet, Pedro Jares, Mireia García, Elena Gonzalvo, Ana Arance, Adriana García, Llucia Alos, Cristina Teixido

Get full text

Abstracts of the XI Forum on Translational Immunology and Cancer Immunotherapy (FIT Cancer 11) by Francisco Aya, Luis de la Cruz, Delvys Rodríguez-Abreu, Luis Álvarez-Vallina, Manel Juan, Elisabeth Pérez-Ruiz, Xabier Mielgo, Rodolfo Chicas-Sett, Ana Arance

Get full text

Abstracts of the X Forum on Translational Immunology and Cancer Immunotherapy (FIT Cancer 10) by Francisco Aya, Luis de la Cruz, Delvys Rodríguez-Abreu, Luis Álvarez-Vallina, Manel Juan, Antonio José Conde-Moreno, Elisabeth Pérez-Ruiz, Xabier Mielgo, Ana Arance

Get full text

Frequency and Clinicopathological Profile Associated with Braf Mutations in Patients with Advanced Melanoma in Spain by Jose A. Lopez-Martin, Ana Arance Fernández, Juan José Ríos-Martín, Javier Hernández-Losa, Lucía Alós Hernández, Pablo Cerezuela Fuentes, Sebastián Ortiz Reina, Eugenia Ortega Izquierdo, Rosa M Martí, Jesús Soberino García, Berta Ferrer Fábrega, José Luis Rodríguez Peralto

Get full text

Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. by Graham Cohen, Bernardo Rapoport, Sze W Chan, Paul Ruff, Ana Arance, Karmele Mujika Eizmendi, Baerin Houghton, Michael P Brown, Robert M Zielinski, Eva Muñoz Couselo, Megan Lyle, James R Anderson, Lokesh Jain, Dinesh de Alwis, Mallika Lala, Omobolaji Akala, Elliot Chartash, Conrad Jacobs

Get full text

Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study by Graham Cohen, Bernardo Rapoport, Sze W. Chan, Paul Ruff, Ana Arance, Karmele Mujika Eizmendi, Baerin Houghton, Michael P. Brown, Robert M. Zielinski, Eva Muñoz Couselo, Megan Lyle, James R. Anderson, Lokesh Jain, Dinesh de Alwis, Mallika Lala, Omobolaji Akala, Elliot Chartash, Conrad Jacobs

Get full text

Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series by Lisa Zimmer, Bastian Schilling, Yinghong Wang, Georgina V Long, Jennifer McQuade, Ana Arance, Douglas B Johnson, Nadia Yousaf, Kazi J Nahar, Matteo S Carlino, Kate Young, Joanna Lee, Liselotte Tas, Serigne N Lo, Christian Blank, Alexander Maxwell Menzies, Catriona Harvey, Janet McKeown, Sheima Farag, Aafke Meerveld-Eggink, Austin Thomas, Roberto Martín Huertas

Get full text

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma by Dirk Schadendorf, Ralf Gutzmer, Caroline Robert, Celeste Lebbe, Gabriella Liszkay, Inge Marie Svane, Omid Hamid, Paolo Antonio Ascierto, Catriona McNeil, Claus Garbe, Michele Maio, Vanna Chiarion-Sileni, Luc Thomas, Andrzej Mackiewicz, Carmen Loquai, Ana Arance, Piotr Rutkowski, Laurent Mortier, Lars Bastholt, Brigitte Dreno, Marta Nyakas, Jean-Jacques Grob, Michael Smylie, Christoph Hoeller, Virginia Ferraresi, Florent Grange, Joanna Pikiel, Fareeda Hosein, Burcin Simsek, Michele Del Vecchio

Get full text

Cross-method comparison for BRAF p.V600 mutation cfDNA testing in Melanoma: BRAFI study by Clara Mayo de las Casas, Eloisa Jantus-Lewintre, Sebastian Ortiz Reina, Ana Drozdowskyj, Pablo Cerezuela-Fuentes, Jose Luis Manzano, Pablo Ayala de Miguel, Ana Arance Fernandez, Miguel Angel Berciano-Guerrero, Almudena Garcia-Castaño, Teresa Puertolas, Guillermo Crespo, Maria Quindos-Varela, Juan Francisco Rodriguez-Moreno, Alfonso Berrocal, Eva Muñoz-Couselo, Enrique Espinosa, Joselyn Valarezo, Susana Muñoz, Silvia Calabuig-Fariñas, Miguel Angel Molina, Rafael Rosell, Joan Anton Puig-Butille, Maria Gonzalez-Cao

Get full text

961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1... by Caroline Robert, Helena Escuin-Ordinas, Juan Martin-Liberal, Miguel Sanmamed, Stephane Dalle, Ana Arance, Marya Chaney, Sorilla Prey, Alfonso Berrocal, Caroline Dutriaux, Iván Márquez Rodas, Philippe Saiag, Luis de la Cruz Merino, Juan Rodríguez-Moreno, Eduardo Castañón Álvarez, Pablo Cerezuela-Fuentes, Henry Montaudie, María González Cao, Julie Charles, María Pilar López Criado, Enrique de Miguel, Elisa Funk-Brentano, Roberto Huertas, Delvys Rodríguez Abreu, Eva Muñoz Couselo, Javier Sánchez López, Sonia Maciá

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial by Paolo A. Ascierto, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Mario Mandalà, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbe, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. Sanmamed, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero, Antonio M. Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni, Giuseppe Palmieri

Get full text